Security Snapshot

AKTIS ONCOLOGY, INC. - Common Stock (AKTSQ) Institutional Ownership

CUSIP: 00973N102

13F Institutional Holders and Ownership History from Q1 2017 to Q2 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.01

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
AKTSQ
Shares outstanding
53,160,953
Price per share
$0.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • AKTSQ - AKTIS ONCOLOGY, INC. - Common Stock is tracked under CUSIP 00973N102.
  • Latest finished 13F holder period is not available.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 2 to 0 between Q1 2025 and Q2 2025.
  • Reported value moved from $186 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 00973N102?
CUSIP 00973N102 identifies AKTSQ - AKTIS ONCOLOGY, INC. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of AKTIS ONCOLOGY, INC. - Common Stock (AKTSQ) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MPM BIOVENTURES 2018, L.P. 19% $102,601 10,260,064 ANSBERT GADICKE 12 Jan 2026
ELI LILLY & Co 12% $63,441 6,344,114 Eli Lilly and Company 12 Jan 2026

Institutional Holders of AKTIS ONCOLOGY, INC. - Common Stock (AKTSQ) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q2 0 $0 -$186 $0.01 0
2025 Q1 28,756 $186 -$2,201 $0.01 2
2024 Q4 506,064 $2,329 -$1,774,940 $0.00 6
2024 Q3 21,200,599 $1,897,435 -$265,185 $0.09 74
2024 Q2 22,552,604 $2,969,307 -$6,536,132 $0.13 86
2024 Q1 40,766,012 $24,082,620 +$6,776,273 $0.59 114
2023 Q4 28,647,438 $23,897,708 -$3,342,214 $0.83 109
2023 Q3 32,959,953 $24,819,558 -$16,320,918 $0.75 115
2023 Q2 37,359,126 $118,771,428 +$4,954,833 $3.18 129
2023 Q1 35,816,573 $110,320,654 +$32,393,447 $3.08 134
2022 Q4 25,954,942 $73,192,741 -$3,031,899 $2.82 118
2022 Q3 28,084,792 $83,413,629 -$1,955,518 $2.97 116
2022 Q2 28,645,141 $105,984,283 -$2,055,220 $3.70 117
2022 Q1 28,817,875 $187,242,534 +$9,205,739 $6.50 125
2021 Q4 27,471,896 $181,648,914 +$4,764,811 $6.68 144
2021 Q3 26,199,923 $251,078,561 +$15,102,389 $9.70 137
2021 Q2 24,628,830 $262,680,830 +$18,492,366 $10.71 135
2021 Q1 20,871,341 $278,313,970 +$45,493,984 $13.34 140
2020 Q4 17,587,930 $215,095,371 +$34,918,930 $12.23 123
2020 Q3 14,858,398 $121,245,735 -$9,234 $8.16 106
2020 Q2 14,645,331 $121,388,588 +$6,390,914 $8.29 107
2020 Q1 14,541,971 $77,997,627 -$7,393,657 $5.37 92
2019 Q4 14,861,013 $118,892,872 +$41,772,041 $8.00 98
2019 Q3 9,599,971 $74,368,610 -$10,612,495 $7.75 86
2019 Q2 11,160,282 $71,421,311 +$28,509,937 $6.40 74
2019 Q1 6,627,920 $38,504,613 +$3,581,540 $5.81 61
2018 Q4 6,194,754 $30,783,708 +$11,758,455 $4.97 52
2018 Q3 3,358,200 $26,439,108 +$938,131 $7.87 38
2018 Q2 3,246,429 $23,591,651 +$953,511 $7.27 36
2018 Q1 3,172,819 $18,477,690 +$2,383,631 $5.83 41
2017 Q4 2,761,631 $17,215,534 +$2,655,569 $6.23 42
2017 Q3 2,097,337 $13,671,502 +$4,486,379 $6.52 33
2017 Q2 1,389,172 $12,132,953 +$3,180,314 $8.74 28
2017 Q1 742,987 $9,416,000 +$9,416,000 $12.84 13
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .